

CANCER DRUG MANUAL

NEW MONOGRAPHS AND PATIENT HANDOUTS

- **Bendamustine Monograph and Handout** have been developed with expert review provided by Dr. Kerry Savage (Medical Oncologist, BCCA Lymphoma Tumour Group).

Bendamustine is an alkylating agent related to mechlorethamine and is used in the treatment of relapsed or refractory non-Hodgkin lymphoma (BCCA Protocol ULYBEND) and chronic lymphocytic leukemia. Myelosuppression is a common side effect, including neutropenia, thrombocytopenia and anemia. Common non-hematological toxicities include nausea, vomiting, fatigue, diarrhea, constipation and pyrexia. Other less common but serious side effects include febrile neutropenia, acute renal failure, cardiac failure, hypertensive crisis, hypersensitivity, skin reactions and pulmonary fibrosis. Bendamustine is a local irritant and post-marketing surveillance has reported marked swelling, pain, and erythema at the injection site. Therefore, infusion sites should be monitored carefully to avoid extravasation.

REVISED MONOGRAPHS AND PATIENT HANDOUTS

- **Cetuximab Monograph**
 - *Mechanism of Actions* – more details added on synergy with radiation therapy
 - *Dosage Guidelines* – timing of cetuximab infusions in relation to radiation therapy clarified. The manufacturer's product monograph states that cetuximab should be given 1 hour before radiation therapy. However, cetuximab has a half-life of 3 to 4 days. Therefore, the *Dosage Guidelines* section has been revised to state that cetuximab may be given at any time on the day of radiation therapy.

BENEFIT DRUG LIST

REVISED PROGRAMS

The following program change has been made on the Benefit Drug List effective 01 May 2013:

Protocol Title	Protocol Code	New Benefit Status
Therapy for High Risk Gestational Trophoblastic Cancer Using CISplatin, Etoposide, DACTINomycin, Methotrexate and Leucovorin	UGOTDHR	Restricted

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed

below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

REVISED PROTOCOLS, PPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UBRAJACTW	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typos corrected</i>	Adjuvant Therapy for Early Breast Cancer using DOXOrubicin and Cyclophosphamide followed by Weekly PACLitaxel
GIEFUPRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Cardiac toxicity updated, DPD deficiency added</i>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal using Mitomycin, Fluorouracil and Radiation Therapy
GIENACTRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Check box for Class II indication added</i>	Neoadjuvant Treatment of Esophageal and Gastroesophageal Carcinomas Using CARBOplatin, PACLitaxel and Radiation Therapy
GIFUFA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Cardiac toxicity updated, DPD deficiency added</i>	Palliative Therapy for Advanced Colorectal Cancer Using Leucovorin and Fluorouracil
GIFUINF	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Cardiac toxicity updated, DPD deficiency added</i>	Palliative Therapy for Metastatic Colorectal Adenocarcinoma Using Fluorouracil Infusional Chemotherapy
UGIYTT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Invoicing procedure updated</i>	Yttrium-90 for Transarterial Radioembolisation (TARE)
UGOOVDDCAT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement clarified in Eligibility</i>	Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using CARBOplatin and Weekly PACLitaxel
GOOVVIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Vinorelbine
UGOTDHR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement added to Eligibility, Protocol code updated, TALLman lettering formatted</i>	Therapy for High Risk Gestational Trophoblastic Cancer
HNSAVNP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Hydration regimen updated</i>	Palliative Treatment of Advanced Salivary Gland Cancers with CISplatin and Vinorelbine

Precautions on cardiac toxicities have been updated for the following fluorouracil- or capecitabine-containing chemotherapy protocols:

CODE	Protocol Title
BRAJCAFG	Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, DOXOrubicin, Fluorouracil and Filgrastim
BRAJCAFPO	Adjuvant Therapy for Breast Cancer using Oral Cyclophosphamide, DOXOrubicin and Fluorouracil

CODE	Protocol Title
BRAJCEFG	Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
BRAJCMF	Adjuvant Therapy for High Risk Breast Cancer Using Cyclophosphamide (IV), Methotrexate and Fluorouracil
BRAJCMFPO	Adjuvant Therapy for High Risk Breast Cancer Using Cyclophosphamide (Oral), Methotrexate and Fluorouracil
BRAJDTFEC	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Trastuzumab, and Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFEC	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECD	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BRAJFECDT	Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab
BRAVCAF	Palliative Therapy for Metastatic Breast Cancer Using Cyclophosphamide, DOXOrubicin and Fluorouracil
BRAVCAP	Therapy for Metastatic Breast Cancer Using Capecitabine
BRAVCMF	Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil
BRAVCMFPO	Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide (Oral), Methotrexate and Fluorouracil
BRAVDCAP	Palliative Therapy for Metastatic Breast Cancer Using DOCEtaxel and Capecitabine
UBRAVLCAP	Therapy for Metastatic Breast Cancer Using Capecitabine and Lapatinib
UBRAVTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Capecitabine
BRINFCAF	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, DOXOrubicin and Fluorouracil
BRINFCEF	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
BRINFCEFG	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
UBRLA2	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, DOXOrubicin and Fluorouracil
UBRLACEF	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
BRLACEFG	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
GIAJCAP	Adjuvant Therapy of Colon Cancer Using Capecitabine
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine
GIAJFFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, 5-Fluorouracil and Folinic Acid
GIAJFL	Adjuvant Therapy of Colon Cancer Using Fluorouracil Injection and Infusion and Folinic Acid (Leucovorin) Infusion
GIAVCAP	Palliative Therapy of Advanced Colorectal Cancer Using Capecitabine
GIAVFL	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Folinic Acid (Leucovorin) Infusion
UGIAVTZCAP	Palliative therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine
UGICAPIRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI

CODE	Protocol Title
UGICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine
GICART	Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy
UGICIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine
UGICOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
GICPART	Combined Modality Therapy for Carcinoma of the Anal Canal using CISplatin, Capecitabine and Radiation Therapy
UGIFIRINOX	Palliative Combination Chemotherapy for Metastatic Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Folinic Acid (Leucovorin)
GIFUART	Combined Modality Therapy for Locally Advanced Esophageal Cancer Using Fluorouracil and CISplatin
GIFUPART	Combined Modality Curative Therapy for Carcinoma of the Anal Canal using CISplatin, Infusional Fluorouracil and Radiation Therapy
GIGAIRT	Combined Modality Adjuvant Therapy for Completely Resected Gastric Adenocarcinoma Using Fluorouracil + Folinic Acid (Leucovorin) and Radiation Therapy
UGIGAJCPRT	Adjuvant Chemotherapy of Gastric Cancer patients with Completely Resected Gastric Cancer using CISplatin and Capecitabine and Radiation Therapy
UGIGAVCCT	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Capecitabine and Trastuzumab
UGIGAVCFT	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab
GIGAVECC	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, CISplatin and Capecitabine
GIGAVECF	Palliative Therapy for Metastatic or Locally Advanced Gastric, Esophagogastric Cancer Using Epirubicin, CISplatin and Infusional 5-Fluorouracil
GIGECC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, CISplatin and Capecitabine
GIGE CF	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, CISplatin and Infusional Fluorouracil
GIRAJCOX	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine
GIRAJFFOX	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, 5-Fluorouracil and Folinic Acid (Leucovorin)
GIRCAP	Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy using Capecitabine
GIRCRT	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine and Radiation Therapy
GIRINFRT	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine, Infusional Fluorouracil and Radiation Therapy
GUFUPRT	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and CISplatin with Radiation
HNAVFUFA	5-Fluorouracil and Leucovorin for Recurrent Head and Neck Cancer (Squamous Cell Carcinoma)
HNAVFUP	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using CISplatin and Fluorouracil
HNLACAFRT	Combined Chemotherapy (CARBOplatin and Fluorouracil) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
UHNLDACF	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with DOCEtaxel, CISplatin and Infusional Fluorouracil
UHNNAVCAP	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Capecitabine

CODE	Protocol Title
HNNAVFUFA	5-Fluorouracil and Leucovorin for Recurrent Head and Neck Cancer (Nasopharyngeal)
HNNAVFUP	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using CISplatin and Fluorouracil
HNSAVFAC	Palliative Therapy for Advanced Salivary Gland Cancers Using Cyclophosphamide, DOXOrubicin and Fluorouracil
HNSAVFUP	Treatment of Advanced Head and Neck Cancer Using CISplatin and Fluorouracil

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sman3@bccancer.bc.ca
Provincial Systemic Therapy Program	250.712.3900 x 686620		mberk@bccancer.bc.ca
Communities Oncology Network (CON)	250.519.5616		jdenduyf@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	1.888.675.8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Man, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Johanna Den Duyf, MA
 Caroline Lohrisch, MD

Beth Morrison, MLS
 Lindsay Schwartz, RN, MScA
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)